Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial

F.H.B.M. Schreuder, K.M. van Nieuwenhuizen, J. Hofmeijer, S.E. Vermeer, H. Kerkhoff, E. Zock, G.J. Luijckx, G.P. Messchendorp, J. van Tuijl, H.P. Bienfait, S.J. Booij, I.R. van den Wijngaard, M.J.M. Remmers, A.H.C.M.L. Schreuder, D.W. Dippel, J. Staals, P.J.A.M. Brouwers, M.J.H. Wermer, J.M. Coutinho, V.I.H. KwaI.C. van Gelder, R.E.G. Schutgens, B. Zweedijk, A. Algra, J.W. van Dalen, L.J. Kappelle, G.J.E. Rinkel, H.B. van Der Worp, C.J.M. Klijn*, APACHE-AF Trial Investigators

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)
Original languageEnglish
Pages (from-to)907-916
Number of pages10
JournalLancet Neurology
Volume20
Issue number11
DOIs
Publication statusPublished - 1 Nov 2021

Keywords

  • ANTITHROMBOTIC TREATMENT
  • INTRACRANIAL HEMORRHAGE
  • SECONDARY PREVENTION
  • ORAL ANTICOAGULANTS
  • VASCULAR EVENTS
  • STROKE

Cite this